0TB Stock Chart & Stats
€14.60
€0.10(0.69%)
At close: 4:00 PM EDT
€14.60
€0.10(0.69%)
Day’s Range― - ―
52-Week Range€11.00 - €17.50
Previous CloseN/A
Volume0.00
Average Volume (3M)16.00
Market Cap
€761.68M
Enterprise Value€562.05
Total Cash (Recent Filing)€387.66M
Total Debt (Recent Filing)€38.57M
Price to Earnings (P/E)16.0
Beta0.78
Next Earnings
Nov 10, 2026EPS Estimate
0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.06
Shares Outstanding51,918,755
10 Day Avg. Volume50
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)3.17
Price to Sales (P/S)8.76
P/FCF Ratio3.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.72Price Target Upside0.85% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)2.3
Revenue Forecast (FY)€95.42M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt relative to equity gives durable financial flexibility. A ~0.06 debt-to-equity ratio reduces refinancing and liquidity risk, supports restructuring and deal execution, and provides capacity to fund milestones or short-term obligations even if operating performance softens.
Positive Trailing Twelve‑month Cash GenerationSustained positive operating and free cash flow over the trailing year materially improves runway and optionality. Consistent cash generation supports near‑term obligations, funds corporate actions, and reduces reliance on external financing versus prior multi‑year cash burn patterns.
Durable Commercial Asset And Strategic Deal Provides ValueYUPELRI is a differentiated, partner‑commercialized respiratory product providing recurring royalties/profit share. The agreed Zymeworks acquisition delivers immediate cash value and a CVR for ampreloxetine, preserving upside while crystallizing the company’s core commercial economics.
Bears Say
Recent Revenue ContractionA shrinkage in trailing revenue erodes the operating base that underpins margins and cash flow. Revenue declines reduce ability to absorb fixed costs, make turnaround plans harder to execute, and increase reliance on one‑off transactions or partner payments to sustain results.
Earnings Quality Concerns (operating Loss Vs Net Income)Positive net income driven in part by non‑operating items while EBIT remains negative signals weaker underlying operating profitability. That divergence raises sustainability questions: earnings and cash conversion could reverse if non‑operating boosts are not repeatable.
Revenue Dependence On Partners And Milestone TimingA business model reliant on partner commercialization, royalties and milestone timing limits direct control over sales and creates counterparty risk. Long‑term performance is therefore sensitive to partner execution and timing of milestone receipts, increasing volatility in results.
Theravance Biopharma News
0TB FAQ
What was Theravance Biopharma’s price range in the past 12 months?
Theravance Biopharma lowest stock price was €11.00 and its highest was €17.50 in the past 12 months.
What is Theravance Biopharma’s market cap?
Theravance Biopharma’s market cap is €761.68M.
When is Theravance Biopharma’s upcoming earnings report date?
Theravance Biopharma’s upcoming earnings report date is Nov 10, 2026 which is in 86 days.
How were Theravance Biopharma’s earnings last quarter?
Theravance Biopharma released its earnings results on Aug 10, 2026. The company reported -€0.095 earnings per share for the quarter, missing the consensus estimate of €0.062 by -€0.158.
Is Theravance Biopharma overvalued?
According to Wall Street analysts Theravance Biopharma’s price is currently Undervalued.
Does Theravance Biopharma pay dividends?
Theravance Biopharma does not currently pay dividends.
What is Theravance Biopharma’s EPS estimate?
Theravance Biopharma’s EPS estimate is 0.21.
How many shares outstanding does Theravance Biopharma have?
Theravance Biopharma has 51,918,755 shares outstanding.
What happened to Theravance Biopharma’s price movement after its last earnings report?
Theravance Biopharma reported an EPS of -€0.095 in its last earnings report, missing expectations of €0.062. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Theravance Biopharma?
Currently, no hedge funds are holding shares in DE:0TB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Theravance Biopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€14.72 (0.85% Upside)
€14.72 (0.85% Upside)
Blogger Sentiment
Neutral
DE:0TB Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €5.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
52.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.27%
Trailing 12-Months
Company Description
Theravance Biopharma
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
0TB Stock 12 Month Forecast
Average Price Target
€14.72
▲(0.85% Upside)